Ceyda Anar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ceyda Anar has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Hüseyin Halilçolar
Department of Chest Diseases, İzmir Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
6 shared publications- Mine Gayaf
Izmir Dr Suat Seren Chest Dis & Thorac Surg Train, Clin Chest Dis, Izmir, Turkey
6 shared publications Filiz Güldaval
5 shared publications- Gülru Polat
Department of Pulmonology, Izmir Dr Suat Seren Chest Disease and Surgery Training and Research Hospital, Health Sciences University, Izmir 35110, Türkiye
4 shared publications Huseyin Halilcolar
Department of Chest Diseases, İzmir Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
4 shared publicationsIpek Unsal
Department of Chest Diseases, İzmir Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
4 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
From guidelines to reality: how do physicians really manage sarcoidosis?
Guidelines exist for the diagnosis, treatment, and follow-up of sarcoidosis; however, considerable variation in clinical practice remains. This study aimed
- 6 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessFrom guidelines to reality: how do physicians really manage sarcoidosis?
Guidelines exist for the diagnosis, treatment, and follow-up of sarcoidosis; however, considerable variation in clinical practice remains. This study aimed
- 10 August 2025
- Published by Taylor & Francis in Physiotherapy Theory and Practice
- Vol. 42 (1) , 1-12
Investigation of metric properties of the Londrina Activities of Daily Living Protocol in patients with idiopathic pulmonary fibrosis
Patients with idiopathic pulmonary fibrosis (IPF) often experience a decline in activities of daily living (ADL) due to progressive lung impairment. Therefore, it is essential to evaluate ADL performance in a way that reflects real-life challenges. This study aims to investigate the metric properties of the Londrina ADL Protocol in patients with IPF. Thirty-three patients (66.7% men, age: 66.7 ± 5.2 years) participated in this observational metric analysis study. We evaluated the protocol's validity, reliability, standard error of measurement (SEM), and minimal detectable change with 95% confidence (MDC95). To assess validity, we calculated correlation coefficients between the Londrina-ADL protocol and the Glittre Test (TGlittre), the 6-Minute Walk Test (6MWT), the London Chest-ADL (LCADL) Scale, hand grip strength, knee extension strength, and respiratory functions. Intra-rater reliability was analyzed using the intraclass correlation coefficient (ICC), paired sample t-test, SEM, MDC95, and the learning effect. The Londrina-ADL protocol showed significant correlations with the TGlittre, the 6MWT, the LCADL, hand grip strength, knee extension strength, and respiratory functions (r = 0.742, r = -0.619, r = 0.665, r = -0.601, r = -0.587, p < .001, respectively.). The protocol demonstrated excellent intra-rater reliability (ICC = 0.939). Test durations differed significantly between tests (p < .001). The SEM and MDC95 values were 8.69 seconds and 24.01 seconds, respectively, with a learning effect of 4.7% observed between the first and second tests. Given its strong metric properties, the Londrina-ADL protocol may serve as a practical and sensitive tool for evaluating daily functional capacity and guiding individualized rehabilitation strategies in patients with IPF.
- 10 August 2025
- Published by Taylor & Francis in Physiotherapy Theory and Practice
- Vol. 42 (1) , 1-12
Investigation of metric properties of the Londrina Activities of Daily Living Protocol in patients with idiopathic pulmonary fibrosis
Patients with idiopathic pulmonary fibrosis (IPF) often experience a decline in activities of daily living (ADL) due to progressive lung impairment. Therefore, it is essential to evaluate ADL performance in a way that reflects real-life challenges. This study aims to investigate the metric properties of the Londrina ADL Protocol in patients with IPF. Thirty-three patients (66.7% men, age: 66.7 ± 5.2 years) participated in this observational metric analysis study. We evaluated the protocol's validity, reliability, standard error of measurement (SEM), and minimal detectable change with 95% confidence (MDC95). To assess validity, we calculated correlation coefficients between the Londrina-ADL protocol and the Glittre Test (TGlittre), the 6-Minute Walk Test (6MWT), the London Chest-ADL (LCADL) Scale, hand grip strength, knee extension strength, and respiratory functions. Intra-rater reliability was analyzed using the intraclass correlation coefficient (ICC), paired sample t-test, SEM, MDC95, and the learning effect. The Londrina-ADL protocol showed significant correlations with the TGlittre, the 6MWT, the LCADL, hand grip strength, knee extension strength, and respiratory functions (r = 0.742, r = -0.619, r = 0.665, r = -0.601, r = -0.587, p < .001, respectively.). The protocol demonstrated excellent intra-rater reliability (ICC = 0.939). Test durations differed significantly between tests (p < .001). The SEM and MDC95 values were 8.69 seconds and 24.01 seconds, respectively, with a learning effect of 4.7% observed between the first and second tests. Given its strong metric properties, the Londrina-ADL protocol may serve as a practical and sensitive tool for evaluating daily functional capacity and guiding individualized rehabilitation strategies in patients with IPF.
- Open Access
- 18 February 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31
Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye
In this study conducted in a single center in Türkiye, we aimed to investigate the effect of sex differences on survival and treatment adverse effects in 100 patients with advanced non-small cell lung carcinoma (NSCLC) treated with immune checkpoint inhibitors. This was a single-center, retrospective, observational study. All 100 patients with non-small cell lung carcinoma admitted to the Pulmonary and Medical Oncology Department of a Training and Research Hospital between January 2018 and March 2024 were evaluated. Demographic data, cancer characteristics, overall survival, and adverse effects of immune checkpoint inhibitors were investigated in the male and female patient groups. Patients were treated with nivolumab and atezolizumab as immune checkpoint inhibitors (ICI). This study included 100 patients, with 88 (88%) men and 12 (12%) women. The average age of the patients was 64.3±8.5 years, 63% had adenocarcinoma, and 80.6% of all patients were stage 4. Although overall survival was significantly lower in women compared to men in univariate analysis (P=0.047), this difference disappeared in multivariate analysis (P=0.168). Adverse effects were observed in 91% of the patients. Pleural effusion (P=0.040), hypothyroidism (P=0.003), and rash (P<0.001) were more common in women, whereas tiredness (P=0.804), pneumonitis (P=0.097), and hyperthyroidism (P=0.507) were not significantly different according to sex. The average follow-up period was 33.8±22.6 months, and 25% of patients died. The association of sex differences with adverse effects and survival in patients with NSCLC receiving ICI treatment is not fully understood. Further studies are needed to support this area of interest.
- 18 February 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31
Open AccessAssociation of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye
In this study conducted in a single center in Türkiye, we aimed to investigate the effect of sex differences on survival and treatment adverse effects in 100 patients with advanced non-small cell lung carcinoma (NSCLC) treated with immune checkpoint inhibitors. This was a single-center, retrospective, observational study. All 100 patients with non-small cell lung carcinoma admitted to the Pulmonary and Medical Oncology Department of a Training and Research Hospital between January 2018 and March 2024 were evaluated. Demographic data, cancer characteristics, overall survival, and adverse effects of immune checkpoint inhibitors were investigated in the male and female patient groups. Patients were treated with nivolumab and atezolizumab as immune checkpoint inhibitors (ICI). This study included 100 patients, with 88 (88%) men and 12 (12%) women. The average age of the patients was 64.3±8.5 years, 63% had adenocarcinoma, and 80.6% of all patients were stage 4. Although overall survival was significantly lower in women compared to men in univariate analysis (P=0.047), this difference disappeared in multivariate analysis (P=0.168). Adverse effects were observed in 91% of the patients. Pleural effusion (P=0.040), hypothyroidism (P=0.003), and rash (P<0.001) were more common in women, whereas tiredness (P=0.804), pneumonitis (P=0.097), and hyperthyroidism (P=0.507) were not significantly different according to sex. The average follow-up period was 33.8±22.6 months, and 25% of patients died. The association of sex differences with adverse effects and survival in patients with NSCLC receiving ICI treatment is not fully understood. Further studies are needed to support this area of interest.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1577
Approaches in diagnosis, follow-up and treatment of patients with progressive pulmonary fibrosis: a questionnaire study
Introduction: Progressive pulmonary fibrosis (PPF) depends on the underlying disease; there is no complete consensus on diagnosis, follow-up, and treatment. We aim to evaluate strategies for PPF patients through a questionnaire. Methods: The link to a web-based questionnaire has been prepared to assess the diagnosis, follow-up, and treatment of patients with PPF. Results: In this study, 91 pulmonologists and 39 rheumatologists completed an online survey. Doing a multidisciplinary council(MDC) in their hospitals’ the rate was 63%; working with a thoracic radiologist, the rate was 71%, and working with pathologists studying interstitial lung diseases’ the rate was 40%. The most common underlying primary diseases were rheumatoid arthritis-associated ILD (46.2%) and systemic sclerosis-associated ILD (45.4%). The methods used during follow-ups were respiratory function tests (90%), DLCO (84%), HRCT (79%), and pulmonary symptoms (79%). Used first-line medications were steroids (85%), and second-line medications were MMF(58.5%). Antifibrotic drug treatment was given by 85% of participants, and 78.5% of them would use a combination of antifibrotic and immunosuppressive agents. While 28% of the participants did not experience any hesitation in diagnosing and treating PPF, the absence of a multidisciplinary team (35%) and the interpretation of radiological findings (31.5%) were the most hesitant situations. Conclusions: In this study, MDC were important for physicians in PPF patients. Although the management of PPF patients varied, the physicians’ approach to diagnosis, follow-up, and treatment of PPF patients was similar to the PPF guidelines’ recommendations.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1577
Approaches in diagnosis, follow-up and treatment of patients with progressive pulmonary fibrosis: a questionnaire study
Introduction: Progressive pulmonary fibrosis (PPF) depends on the underlying disease; there is no complete consensus on diagnosis, follow-up, and treatment. We aim to evaluate strategies for PPF patients through a questionnaire. Methods: The link to a web-based questionnaire has been prepared to assess the diagnosis, follow-up, and treatment of patients with PPF. Results: In this study, 91 pulmonologists and 39 rheumatologists completed an online survey. Doing a multidisciplinary council(MDC) in their hospitals’ the rate was 63%; working with a thoracic radiologist, the rate was 71%, and working with pathologists studying interstitial lung diseases’ the rate was 40%. The most common underlying primary diseases were rheumatoid arthritis-associated ILD (46.2%) and systemic sclerosis-associated ILD (45.4%). The methods used during follow-ups were respiratory function tests (90%), DLCO (84%), HRCT (79%), and pulmonary symptoms (79%). Used first-line medications were steroids (85%), and second-line medications were MMF(58.5%). Antifibrotic drug treatment was given by 85% of participants, and 78.5% of them would use a combination of antifibrotic and immunosuppressive agents. While 28% of the participants did not experience any hesitation in diagnosing and treating PPF, the absence of a multidisciplinary team (35%) and the interpretation of radiological findings (31.5%) were the most hesitant situations. Conclusions: In this study, MDC were important for physicians in PPF patients. Although the management of PPF patients varied, the physicians’ approach to diagnosis, follow-up, and treatment of PPF patients was similar to the PPF guidelines’ recommendations.
- Open Access
- 31 January 2024
- Published by Wiley
The Effect of Host Risk Factors in Determining the Mortality in Covid 19 Pneumonia and a Novel Covid-19 Mortality Index: Co-AMSCA
Aim:The purpose of this study was to determine the host risk factors associated with mortality in COVID-19 patients who are hospitalized for pneumonia, and also, to find a COVID-19 mortality score based on these. Methods:All patients diagnosed as confirmed or probable COVID-19 pneumonia whom hospitalised in our Chest Diseases Education and Research Hospital between March 11, 2020 and October 1,2020 were enrolled. The optimal cut-off values, sensitivity and specificity values and odds ratios to be used in mortality prediction of the novel scoring system created from these parameters were calculated by ROC analysis according to the area under the curve and Youden index. Results:Over 422 patients (n: 51 mortal, n: 371 survivors) univariate regression analysis showed that age, male gender, smoking, comorbidity, and using ACE inhibitor were prognostic host risk factors for COVID-19-related mortality. Using this analysis, a novel scoring model Co-AMSCA (Age, Male, Smoking history, Comorbidity, ACE inh)was established. The cut-off value of this scoring system (including only host risk factors), which determines the mortality risk in patients, was 3.5 points with 88.4% sensitivity and 65.5 % specificity (AUC = 0.761, 95% CI 0.697-0.826, P < .001) (Figure 1). The mortality risk in patients with a Co-AMSCA mortality score above 3.5 points was 7.8 times higher than patients with lower than 3.5 (OR= 7.8; P < .001).In multivariate logistic regression analysis, older age and smoking (smoker/ex-smoker) were found to be important risk factors for mortality (OR = 12.09; 95% CI 2,564-57,054 P =0.004 and OR = 3.1; 95% CI 1,381-7,295; P = 0.007,respectively). Counclusion:We created a simple mortality score, which is easily calculated and does not require laboratory and time.This study showed that by using Co-AMSCA mortality score that has only host risk factors achieved a prediction of mortality in COVID-19 patients who are hospitalized for pneumonia.
- 31 January 2024
- Published by Wiley
Open AccessThe Effect of Host Risk Factors in Determining the Mortality in Covid 19 Pneumonia and a Novel Covid-19 Mortality Index: Co-AMSCA
Aim:The purpose of this study was to determine the host risk factors associated with mortality in COVID-19 patients who are hospitalized for pneumonia, and also, to find a COVID-19 mortality score based on these. Methods:All patients diagnosed as confirmed or probable COVID-19 pneumonia whom hospitalised in our Chest Diseases Education and Research Hospital between March 11, 2020 and October 1,2020 were enrolled. The optimal cut-off values, sensitivity and specificity values and odds ratios to be used in mortality prediction of the novel scoring system created from these parameters were calculated by ROC analysis according to the area under the curve and Youden index. Results:Over 422 patients (n: 51 mortal, n: 371 survivors) univariate regression analysis showed that age, male gender, smoking, comorbidity, and using ACE inhibitor were prognostic host risk factors for COVID-19-related mortality. Using this analysis, a novel scoring model Co-AMSCA (Age, Male, Smoking history, Comorbidity, ACE inh)was established. The cut-off value of this scoring system (including only host risk factors), which determines the mortality risk in patients, was 3.5 points with 88.4% sensitivity and 65.5 % specificity (AUC = 0.761, 95% CI 0.697-0.826, P < .001) (Figure 1). The mortality risk in patients with a Co-AMSCA mortality score above 3.5 points was 7.8 times higher than patients with lower than 3.5 (OR= 7.8; P < .001).In multivariate logistic regression analysis, older age and smoking (smoker/ex-smoker) were found to be important risk factors for mortality (OR = 12.09; 95% CI 2,564-57,054 P =0.004 and OR = 3.1; 95% CI 1,381-7,295; P = 0.007,respectively). Counclusion:We created a simple mortality score, which is easily calculated and does not require laboratory and time.This study showed that by using Co-AMSCA mortality score that has only host risk factors achieved a prediction of mortality in COVID-19 patients who are hospitalized for pneumonia.
- 24 August 2022
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 40 (4) , 577-581
Antibiotic resistance rates and penicillin MIC distribution in patients with streptococcal pneumonia between 2013-2019, and use of antibiotics in clinical practice
- 24 August 2022
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 40 (4) , 577-581
Antibiotic resistance rates and penicillin MIC distribution in patients with streptococcal pneumonia between 2013-2019, and use of antibiotics in clinical practice
- 20 December 2021
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 69 (4) , 437-448
Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer
Introduction: The aim of this study was to evaluate the association between the presence of EGFR mutations, ALK rearrangement and the standardized uptake value (SUV) of 18F-fluoro-2-deoxy-glucose (18F-FDG) by PET/CT imaging in patients with NSCLC. Materials and Methods: We retrospectively reviewed NSCLC patients, who underwent EGFR mutation, ALK rearrangement testing and pre-treatment PET/ CT. The relationships of EGFR mutation, ALK rearrangement with patient cha-racteristics and three parameters based on 18F-FDG PET/CT, including the maximal standard uptake value (SUVmax) of the primary tumour (tSUVmax), lymph node (nSUVmax) and distant metastasis (mSUVmax) were evaluated. Results: EGFR mutations were found more frequently in females and non-smokers. tSUVmax was the only PET parameter that was lower in EGFR-positive patients than in EGFR-negative patients (8.7 vs. 11), with a p value of 0.032. There were no differences between nSUVmax and mSUVmax results and EGFR mutation. tSUVmax, nSUVmax and mSUVmax were not significantly different between ALK positive and ALK negative groups in NSCLC. The presen-ce of pleural fluid at the time of diagnosis was significantly associated with positive ALK expression. Conclusion: We showed that low tSUVmax and primary tumour diameter were associated with mutant EGFR status and could be evaluated with other clinical factors to increase the discrimination in EGFR mutation status in some NSCLC patients without EGFR testing. There is a cor- relation between ALK positivity and the presence of pleural fluid. We also noted that the ALK positivity might be only in the adeno- carcinoma group and at a younger age.
- 20 December 2021
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 69 (4) , 437-448
Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer
Introduction: The aim of this study was to evaluate the association between the presence of EGFR mutations, ALK rearrangement and the standardized uptake value (SUV) of 18F-fluoro-2-deoxy-glucose (18F-FDG) by PET/CT imaging in patients with NSCLC. Materials and Methods: We retrospectively reviewed NSCLC patients, who underwent EGFR mutation, ALK rearrangement testing and pre-treatment PET/ CT. The relationships of EGFR mutation, ALK rearrangement with patient cha-racteristics and three parameters based on 18F-FDG PET/CT, including the maximal standard uptake value (SUVmax) of the primary tumour (tSUVmax), lymph node (nSUVmax) and distant metastasis (mSUVmax) were evaluated. Results: EGFR mutations were found more frequently in females and non-smokers. tSUVmax was the only PET parameter that was lower in EGFR-positive patients than in EGFR-negative patients (8.7 vs. 11), with a p value of 0.032. There were no differences between nSUVmax and mSUVmax results and EGFR mutation. tSUVmax, nSUVmax and mSUVmax were not significantly different between ALK positive and ALK negative groups in NSCLC. The presen-ce of pleural fluid at the time of diagnosis was significantly associated with positive ALK expression. Conclusion: We showed that low tSUVmax and primary tumour diameter were associated with mutant EGFR status and could be evaluated with other clinical factors to increase the discrimination in EGFR mutation status in some NSCLC patients without EGFR testing. There is a cor- relation between ALK positivity and the presence of pleural fluid. We also noted that the ALK positivity might be only in the adeno- carcinoma group and at a younger age.
- Open Access
- 1 October 2021
- Published by Medknow in The Egyptian Journal of Chest Diseases and Tuberculosis
- Vol. 70 (4) , 547-553
Diagnostic value of pleural fluid lactate dehydrogenase/adenosine deaminase ratio in differentiating parapneumonic effusion from tuberculous pleurisy
Objective: The purpose of this study was to determine the diagnostic value of pleural fluid lactate dehydrogenase (LDH)/pleural fluid adenosine deaminase (ADA) ratio in differentiating pleural effusions owing to tuberculous pleurisy (TBP) and parapneumonic effusion (PPE). Patients and methods: The data of 272 patients (140 patients with TBP and 132 patients with PPE) between January 2012 and October 2018 were analyzed retrospectively. Demographic data of all patients; concurrent serum glucose, albumin, protein, and LDH values; and pleural fluid pH, glucose, albumin, protein, and ADA results have been reviewed. Results: Pleural fluid ADA values were statistically significantly higher in the TBP group than PPE (PPP<0.001). Conclusion: The ratio of pleural fluid LDH/ADA determined from routine biochemical analysis predicts TBP at value of 28. Measurement of this parameter may help clinicians distinguish between TBP and PPE.
- 1 October 2021
- Published by Medknow in The Egyptian Journal of Chest Diseases and Tuberculosis
- Vol. 70 (4) , 547-553
Open AccessDiagnostic value of pleural fluid lactate dehydrogenase/adenosine deaminase ratio in differentiating parapneumonic effusion from tuberculous pleurisy
Objective: The purpose of this study was to determine the diagnostic value of pleural fluid lactate dehydrogenase (LDH)/pleural fluid adenosine deaminase (ADA) ratio in differentiating pleural effusions owing to tuberculous pleurisy (TBP) and parapneumonic effusion (PPE). Patients and methods: The data of 272 patients (140 patients with TBP and 132 patients with PPE) between January 2012 and October 2018 were analyzed retrospectively. Demographic data of all patients; concurrent serum glucose, albumin, protein, and LDH values; and pleural fluid pH, glucose, albumin, protein, and ADA results have been reviewed. Results: Pleural fluid ADA values were statistically significantly higher in the TBP group than PPE (PPP<0.001). Conclusion: The ratio of pleural fluid LDH/ADA determined from routine biochemical analysis predicts TBP at value of 28. Measurement of this parameter may help clinicians distinguish between TBP and PPE.
- 14 July 2021
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 22 (4) , 284-288
What are the Differences Between Smoker and Non-smoker COPD Cases? Is it a Different Phenotype?
Chronic obstructive pulmonary disease,smoker,non-smoker
- 14 July 2021
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 22 (4) , 284-288
What are the Differences Between Smoker and Non-smoker COPD Cases? Is it a Different Phenotype?
Chronic obstructive pulmonary disease,smoker,non-smoker
- 15 June 2021
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 69 (2) , 133-143
Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/ lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
The aim of this study was to evaluate the predictive power of LENT (LDH in pleural fluid, Eastern Cooperative Oncology Group [ECOG] performance status, neutrophil-lymphocyte ratio in the serum, and tumor type) score which is a current prognostic score in patients with MPE and to determine its effect on survival and its status in clinical decision making. In addition, it was aimed to compare LENT score with the conventional but subjective score ECOG. A retrospective observational study was conducted reviewing the medical records of patients managed for MPE (malign pleural effusion) between 2008 and 2018. LENT prognostic score was calculated in the patients. The ECOG score calculated for the same patients was compared in terms of mortality. A total of 191 patients with malignant pleural effusion, 118 males (61.7%) and 73 females (38.2%), were included in the study. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying overall survival were 69.8 %, 100%, 100% and 18.8%, respectively at the LENT score > 4 (p= 0.000). At ECOG PS >2, the sensitivity, specificity, PPV, NPV were as the same as the LENT score >4 for identifying overall survival. In all patients, overall median survival according to the LENT score was 662/119/33 days in low/moderate/high risk groups, respectively. Cox regression analysis indicated that having a moderate LENT score (p= 0.004, OR: 2.21, CI: 1.29 -3.78%) and high LENT score (p= 0.000, OR: 4, 50 CI: 2.57-7.89%) were predictors for overall survival in all patients due to MPE. In ROC analysis, there was no difference in mortality in erms of both LENT and ECOG at 1st, 6th and 12th months. LENT is a better scoring system than ECOG in predicting early mortality, while both ECOG and LENT have almost the same power in predicting mortality. However, LENT is slightly more objective but more difficult to calculate because it contains laboratory findings. Thus, both scoring systems can be used to predict mortality in patients with malignant pleural effusions. Neither of them has superiority to each other.
- 15 June 2021
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 69 (2) , 133-143
Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/ lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
The aim of this study was to evaluate the predictive power of LENT (LDH in pleural fluid, Eastern Cooperative Oncology Group [ECOG] performance status, neutrophil-lymphocyte ratio in the serum, and tumor type) score which is a current prognostic score in patients with MPE and to determine its effect on survival and its status in clinical decision making. In addition, it was aimed to compare LENT score with the conventional but subjective score ECOG. A retrospective observational study was conducted reviewing the medical records of patients managed for MPE (malign pleural effusion) between 2008 and 2018. LENT prognostic score was calculated in the patients. The ECOG score calculated for the same patients was compared in terms of mortality. A total of 191 patients with malignant pleural effusion, 118 males (61.7%) and 73 females (38.2%), were included in the study. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying overall survival were 69.8 %, 100%, 100% and 18.8%, respectively at the LENT score > 4 (p= 0.000). At ECOG PS >2, the sensitivity, specificity, PPV, NPV were as the same as the LENT score >4 for identifying overall survival. In all patients, overall median survival according to the LENT score was 662/119/33 days in low/moderate/high risk groups, respectively. Cox regression analysis indicated that having a moderate LENT score (p= 0.004, OR: 2.21, CI: 1.29 -3.78%) and high LENT score (p= 0.000, OR: 4, 50 CI: 2.57-7.89%) were predictors for overall survival in all patients due to MPE. In ROC analysis, there was no difference in mortality in erms of both LENT and ECOG at 1st, 6th and 12th months. LENT is a better scoring system than ECOG in predicting early mortality, while both ECOG and LENT have almost the same power in predicting mortality. However, LENT is slightly more objective but more difficult to calculate because it contains laboratory findings. Thus, both scoring systems can be used to predict mortality in patients with malignant pleural effusions. Neither of them has superiority to each other.